Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

Arexvy是全球首款RSV疫苗，其获批基于在60岁及以上成人中的显著效力，包括因患有某些基础疾病的高风险人群。今日公布的结果显示，接种GSK单剂RSV疫苗在三个RSV完整流行季中的累积保护效力具有临床意义。与安慰剂相比，该疫苗对于RSV引发的下呼吸 ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

编者按：呼吸道合胞病毒（RSV）作为一种对婴幼儿及免疫功能不全人群构成重大威胁的呼吸道病原体，近年来其疫苗和单克隆抗体的研发取得了诸多进展。在刚结束的2024年美国感染性疾病周（IDWeek 2024）上，多项关于儿童RSV防治的最新研究成果备受瞩目 ...

The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

“This is the first time Alberta has included the RSV vaccine in its publicly funded immunization program for seniors, ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...